Cargando…
Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial
BACKGROUND: Alström syndrome (ALMS) is a very rare autosomal recessive monogenic disorder caused by a mutation in the ALMS1 gene and characterised by childhood onset obesity, dyslipidaemia, advanced non-alcoholic fatty liver disease, diabetes and extreme insulin resistance. There is evidence of mult...
Autores principales: | Baig, Shanat, Veeranna, Vishy, Bolton, Shaun, Edwards, Nicola, Tomlinson, Jeremy W., Manolopoulos, Konstantinos, Moran, John, Steeds, Richard P., Geberhiwot, Tarekegn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258144/ https://www.ncbi.nlm.nih.gov/pubmed/30477455 http://dx.doi.org/10.1186/s12902-018-0315-6 |
Ejemplares similares
-
Prospective cardiovascular magnetic resonance imaging in adults with Alström syndrome: silent progression of diffuse interstitial fibrosis
por: Baig, Shanat, et al.
Publicado: (2020) -
Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance
por: Geberhiwot, Tarekegn, et al.
Publicado: (2021) -
Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis
por: Khalil, Nasreen, et al.
Publicado: (2019) -
Alström syndrome: a paradigm for diffuse fibrosis and clinical progression
por: Edwards, Nicola C, et al.
Publicado: (2013) -
Diffuse left ventricular interstitial fibrosis is associated with sub-clinical myocardial dysfunction in Alström Syndrome: an observational study
por: Edwards, Nicola C., et al.
Publicado: (2015)